Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk. The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 3
Maximum Age: 14
Healthy Volunteers: f
View:

• Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005):

‣ High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation

⁃ Moderate/Low risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.

⁃ No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.

Locations
Other Locations
Belgium
Universitair Ziekenhuis Antwerpen
RECRUITING
Antwerp
Hôpital Universitaire Reine Fabiola (HUDERF)
RECRUITING
Brussels
Universitair Ziekenhuis Brussels
RECRUITING
Brussels
UZ-Gent
NOT_YET_RECRUITING
Ghent
Universitair Ziekenhuis Leuven
RECRUITING
Leuven
Centre Hospitalier Régional (CHR)-Citadelle
RECRUITING
Liège
Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance
RECRUITING
Montegnée
France
Centre Oscar Lambret
RECRUITING
Lille
CHRU Lille-Hôpital Jeanne de Flandre
RECRUITING
Lille
Hôpital Robert Debré
NOT_YET_RECRUITING
Paris
Contact Information
Primary
Isabelle Demeestere, PhD
idemeest@ulb.ac.be
+32 2 555 65 92
Backup
Julie Dechene
jdechene@ulb.ac.be
+32 2 555 63 58
Time Frame
Start Date: 2014-04
Estimated Completion Date: 2036-12
Participants
Target number of participants: 275
Treatments
High risk
Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
Moderate/low risk
Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.~This is the study group we will compare with high risk and no risk patients. No intervention
No risk
Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.~No intervention
Related Therapeutic Areas
Sponsors
Collaborators: Queen Fabiola Children's University Hospital
Leads: Erasme University Hospital

This content was sourced from clinicaltrials.gov